{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Percentage of patients who received consolidation with high dose therapy and autologous stem cell rescue (HDT/SCR).","groups":[{"description":"\"A\" Treatment: Cyclophosphamide,Etoposide, Vincristine and Prednisone (CEOP) \"B\" Treatment: Pralatrexate (P)\n\n\"A\" cycles (CEOP) of the treatment regimen are 14 days, followed by \" B\" cycles (P) which are 21 days, followed by 7 days of rest for a total of 42 days per course, unless criteria are met for stopping or holding treatment or to a maximum of 6 courses.\n\nPatients with Complete Response (CR) or Partial Response (PR), per investigators discretion, may then undergo hematopoietic stem cell collection and administration of standard preparative regimen followed by hematopoietic stem cell transplantation.","id":"OG000","title":"Treatment"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Thirty-three patients were analyzed. One patient withdrew consent before starting therapy.","reportingStatus":"POSTED","timeFrame":"168-252 days (4 courses up to 6 courses of treatment)","title":"Percent of Patients Who Proceeded With Transplant","type":"SECONDARY","unitOfMeasure":"Participants"}